Cardiovascular Benefits of New Antidiabetic Drug Classes: A Network Meta-analysis

Cardiovascular Benefits of New Antidiabetic Drug Classes: A Network Meta-analysis

Bibliographic Details
Main Authors:	BMY Cheung, Y Fei, MF Tsoi
Format:	Article
Language:	English
Published:	Radcliffe Medical Media 2020-05-01
Series:	European Cardiology Review
Online Access:	https://www.ecrjournal.com/articleindex/ecr.2020.15.1.PO17

Similar Items

Posters from the 24th Annual Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy
by: BMY Cheung, et al.
Published: (2020-05-01)

Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
by: Chris Wai Hang Lo, et al.
Published: (2021-03-01)

Pharmacogenetics of new classes of antidiabetic drugs
by: Selma Imamovic Kadric, et al.
Published: (2021-12-01)

Blood Lead Level and Hypertension Risk in the United States National Health Nutrition and Examination Survey (NHANES) 1999–2016
by: BMY Cheung, et al.
Published: (2020-05-01)

Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.
by: Gyeongsil Lee, et al.
Published: (2017-01-01)

Meta‐analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes
by: Georg Wolff, et al.
Published: (2023-02-01)

The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects—A Family Doctor Perspective
by: Tomislav Kurevija, et al.
Published: (2024-03-01)

New trends in the development of oral antidiabetic drugs.
by: Kecskemeti, V, et al.
Published: (2002)

Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis
by: Matteo Pagnesi, et al.
Published: (2022-01-01)

Nephroprotective Properties of Antidiabetic Drugs
by: Christian Gerdes, et al.
Published: (2023-05-01)

Antidiabetic drugs and kidney disease
by: Anne Zanchi, et al.
Published: (2012-09-01)

Effect of Oral Antidiabetic Drugs on Tuberculosis Risk and Treatment Outcomes: Systematic Review and Meta-Analysis
by: Edinson Dante Meregildo-Rodriguez, et al.
Published: (2022-10-01)

Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis
by: Eugenia Piragine, et al.
Published: (2023-03-01)

Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
by: Jaime Sanz-Cánovas, et al.
Published: (2023-02-01)

Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom
by: Vanessa C. Brunetti, et al.
Published: (2022-09-01)

Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis
by: Luyuan Tan, et al.
Published: (2024-01-01)

Genetically proxied antidiabetic drugs targets and stroke risk
by: Yahui Zhu, et al.
Published: (2023-09-01)

Effects of antidiabetic drugs on bone metabolism
by: Padilla Apuntate Nuria, et al.
Published: (2024-04-01)

Antidiabetic Drugs in Breast Cancer Patients
by: Wojciech Garczorz, et al.
Published: (2024-01-01)

Antidiabetic Drugs in the Treatment of Alzheimer’s Disease
by: Michalis Michailidis, et al.
Published: (2022-04-01)

Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs
by: Jörg König, et al.
Published: (2011-10-01)

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
by: Angelo Avogaro
Published: (2018-11-01)

Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
by: Amelia D. Dahlén, et al.
Published: (2022-01-01)

Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Artur Małyszczak, et al.
Published: (2024-03-01)

Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs
by: Vallo Volke, et al.
Published: (2022-10-01)

Prospects of antidiabetic drugs in the treatment of neurodegenerative disease
by: Lidan Hu, et al.
Published: (2024-03-01)

Emerging role of antidiabetic drugs in cardiorenal protection
by: Wen-Jia Fu, et al.
Published: (2024-02-01)

Effect of antidiabetic drug treatment on heart failure
by: Hugo Sanabria
Published: (2022-09-01)

SGLT2 inhibitors: a promising class of antidiabetic agents
by: Camelia DIACONU
Published: (2018-12-01)

Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins
by: Anna Gumieniczek, et al.
Published: (2023-07-01)

Comparative analysis of newer classes of antidiabetics and the concept of pharmaceutical care – dealing with therapeutic problems
by: Anna Peneva, et al.
Published: (2024-02-01)

ANALYSIS OF ANTIDIABETIC DRUGS ASSORTMENT REPRESENTED ON THE PHARMACEUTICAL MARKET OF SAINT PETERSBURG
by: Yu. V. Miroshnichenko, et al.
Published: (2015-10-01)

Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data
by: Brockmeyer, M, et al.
Published: (2024)

A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
by: Jelena Vekic, et al.
Published: (2022-01-01)

The benefits of black rice bran and the potential of its bioactive compounds as antidiabetic agents
by: Rafika Eviana, et al.
Published: (2023-06-01)

Carbohydrate digestive enzyme inhibition, hepatoprotective, antioxidant and antidiabetic benefits of Persea americana
by: Christian Omonzokpea Ehikioya, et al.
Published: (2023-01-01)

Electrochemical Assays for the Determination of Antidiabetic Drugs—A Review
by: Katarzyna Fendrych, et al.
Published: (2023-12-01)

Metformin: A Reflection on My Journey as Antidiabetic Drug
by: Gurudas Khilnani
Published: (2023-06-01)

Optimizing weight control in diabetes: antidiabetic drug selection
by: S Kalra, et al.
Published: (2010-08-01)

Optimizing weight control in diabetes: antidiabetic drug selection
by: Kalra S
Published: (2010-08-01)